Evidence map›Paper›PMID 34212072›Full record

ArticleAdvanced materials technologies2021

Covalent Chemistry-Mediated Multimarker Purification of Circulating Tumor Cells Enables Noninvasive Detection of Molecular Signatures of Hepatocellular Carcinoma.

Na Sun, Yi-Te Lee, Minhyung Kim, Jasmine J Wang, Ceng Zhang, Pai-Chi Teng, Dongping Qi, Ryan Y Zhang, Benjamin V Tran, Yue Tung Lee and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced materials technologies, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Na Sun *California NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), 570 Westwood Plaza, Los Angeles, CA 90095, USA.
Yi-Te Lee *California NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), 570 Westwood Plaza, Los Angeles, CA 90095, USA.
Minhyung Kim *Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Jasmine J WangCedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Ceng ZhangCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), 570 Westwood Plaza, Los Angeles, CA 90095, USA.
Pai-Chi TengCedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Dongping QiCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), 570 Westwood Plaza, Los Angeles, CA 90095, USA.
Ryan Y ZhangCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), 570 Westwood Plaza, Los Angeles, CA 90095, USA.
Benjamin V TranDepartment of Surgery, UCLA, 200 Medical Plaza, Los Angeles, CA, 90024, USA.
Yue Tung LeeCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), 570 Westwood Plaza, Los Angeles, CA 90095, USA.
Jinglei YeCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), 570 Westwood Plaza, Los Angeles, CA 90095, USA.
Juvelyn PalomiqueComprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Nicholas N NissenComprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Steven-Huy B HanDepartment of Surgery, UCLA, 200 Medical Plaza, Los Angeles, CA, 90024, USA.
Saeed SadeghiDepartment of Surgery, UCLA, 200 Medical Plaza, Los Angeles, CA, 90024, USA.
Richard S FinnDepartment of Surgery, UCLA, 200 Medical Plaza, Los Angeles, CA, 90024, USA.
Sammy SaabDepartment of Surgery, UCLA, 200 Medical Plaza, Los Angeles, CA, 90024, USA.
Ronald W BusuttilDepartment of Surgery, UCLA, 200 Medical Plaza, Los Angeles, CA, 90024, USA.
Edwin M PosadasCedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Li LiangDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong Province, P.R. China.
Renjun PeiKey Laboratory for Nano-Bio Interface, Suzhou Institute of Nano-Tech and Nano-Bionics, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Suzhou 215123, P.R. China.
Ju Dong YangComprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Sungyong YouCedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Vatche G AgopianDepartment of Surgery, UCLA, 200 Medical Plaza, Los Angeles, CA, 90024, USA.
Hsian-Rong TsengCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), 570 Westwood Plaza, Los Angeles, CA 90095, USA.
Yazhen ZhuCalifornia NanoSystems Institute, Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), 570 Westwood Plaza, Los Angeles, CA 90095, USA.

Funding

Non-Invasive Prenatal Diagnostics Based on Circulating TrophoblastsU01EB026421 · NIBIB · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PISARSKA, MARGARETA, TSENG, HSIAN-RONG · 2019 to 2023
$4.0M
HCC EV Digital Scoring Assay for assessing treatment response in HCC patientsR01CA253651 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TSENG, HSIAN-RONG, ZHU, YAZHEN · 2020 to 2024
$3.3M
Extracellular Vesicle-Based Digital Scoring Assay for Detecting Early-stage Hepatocellular CarcinomaR01CA255727 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZHU, YAZHEN · 2021 to 2025
$3.2M
A blood test to identify prostate cancer patients at risk for visceral metastasisR01CA218356 · NCI · CEDARS-SINAI MEDICAL CENTER · PI POSADAS, EDWIN MELENCIO, TSENG, HSIAN-RONG · 2017 to 2021
$3.0M
Integrated analysis of HCC CTCs for Liver Transplant Candidate SelectionR01CA246304 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AGOPIAN, VATCHE, TSENG, HSIAN-RONG · 2020 to 2024
$2.8M
Thermoresponsive NanoVelcro CTC Purification System for Prostate Cancer ProfilingU01CA198900 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI POSADAS, EDWIN MELENCIO, TSENG, HSIAN-RONG · 2015 to 2019
$2.4M
Click Chemistry-Mediated Microfluidic Sorting for HCC CTCsR21CA235340 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AGOPIAN, VATCHE, TSENG, HSIAN-RONG · 2019 to 2021
$543k
Biomimetic NanoVilli Chips for Extracellular Vesicles in Hepatocellular CarcinomaR21CA240887 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AGOPIAN, VATCHE, TSENG, HSIAN-RONG · 2020 to 2021
$419k
Analysis of HCC CTC Phenotype for Liver Transplant Candidate SelectionR21CA216807 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AGOPIAN, VATCHE · 2018 to 2019
$368k
NCI NIH HHS R01 CA218356NCI NIH HHS R01 CA246304NCI NIH HHS R01 CA253651NCI NIH HHS R01 CA255727NCI NIH HHS R21 CA216807NCI NIH HHS R21 CA235340NCI NIH HHS R21 CA240887NCI NIH HHS U01 CA198900NIBIB NIH HHS U01 EB026421
6 · The paper itself

Abstract

Transcriptomic profiling of tumor tissues introduces a large database, which has led to improvements in the ability of cancer diagnosis, treatment, and prevention. However, performing tumor transcriptomic profiling in the clinical setting is very challenging since the procurement of tumor tissues is inherently limited by invasive sampling procedures. Here, we demonstrated the feasibility of purifying hepatocellular carcinoma (HCC) circulating tumor cells (CTCs) from clinical patient samples with improved molecular integrity using Click Chips in conjunction with a multimarker antibody cocktail. The purified CTCs were then subjected to mRNA profiling by NanoString nCounter platform, targeting 64 HCC-specific genes, which were generated from an integrated data analysis framework with 8 tissue-based prognostic gene signatures from 7 publicly available HCC transcriptomic studies. After bioinformatics analysis and comparison, the HCC CTC-derived gene signatures showed high concordance with HCC tissue-derived gene signatures from TCGA database, suggesting that HCC CTCs purified by Click Chips could enable the translation of HCC tissue molecular profiling into a noninvasive setting.

Indexed as

circulating tumor cellsclick chemistryhepatocellular carcinomananosubstratetranscriptome profiling

Identifiers

PMID34212072
PMCPMC8240468

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.